Genmab — September 2020
-
God morgen.
-
kkjoel. Enig. David er stærk på Genmab.
-
JNJ progressing Teclistamab into a PhII trial https://clinicaltrials.gov/ct2/show/NCT04557098?term=Teclistamab&draw=2&rank=1
-
Combo of ADC Amivantamab & Lazertinib looks good for Osi resistant #EGFR+ #lungcancer. 36% ORR & 100% in treatment naive pts! Questions remain about mech of resistance & use of 1st line BUT as patient I’m a bit concerned about toxicities! https://twitter.com/jillfeldman4/status/1307671624435589120?s=21
-
CHRYSALIS Amivantamab + lazeritinib. Looks a bit toxic to me. Active is Osimertinib resistance. 100% RR in treatment naive! https://twitter.com/drriyazshah/status/1307662972429500418?s=21
-
MET inhibition + double EGFR inhibition is a win.
Amivantamab (bispecific EGFR/MET Ab)+ Lazertinib (3rd gen TKI) rescue osimertinib resistant pts with EGFRmut NSCLC: ORR 36%.
Will be compared to osi 1st line in a Phase III trial.
Dual EGFR/MET tox to be followed... https://twitter.com/benjaminbessemd/status/1307672214972641280?s=21 -
Nice data for$JNJ amivantamab and lazertinib - looks good for post $AZN @TAGRISSO_AZ and also for treatment naïve patients. JNJ certainly has the hope of beating Tagrisso with a head to head phase III. https://twitter.com/samfazeli8/status/1307663441210019840?s=21
-
#Amivantanab in Combination with Lazertinib
Exciting data in Osimertinib-resistan pts
ORR 36%
6% of discontinuation due AEsExcellent data for the EGFR community https://twitter.com/apassaromd/status/1307663461070106626?s=21
-
Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer https://www.prnewswire.com/news-releases/janssen-presents-findings-from-global-multi-center-trial-examining-amivantamab-in-combination-with-lazertinib-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-301134336.html
-
-
Kan kke huske om dette fra bl.a. Ola Landgren har været nævnt: Ola Landgren, M.D.:
Evidence of strong clinical benefit when using CD38 targeted monoclonal antibody (daratumumab) in two patients with refractory, life-threatening Systemic Lupus Erythematosus (SLE). May become an important treatment strategy for many autoimmune diseases in the future? -
God morgen.
-
Servicemeddelelse: Jeg har de seneste uger tegnet nye partneraftaler og et større antal annoncer for det kommende år. Dermed bliver det ikke nødvendigt med donationer længere. På et et tidspunkt vil jeg muligvis indføre et frivilligt support-abonnement til en fast lav pris. Tak for jeres støtte. Uden den - intet PI.
-
Tillykke Helge
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind